Company news

Chimeric Therapeutics Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Patent received in Japan for CLTX CAR technology

August 2, 2022

Licenses viral vector technology from Penn for CDH17

June 28, 2022

A$30 million Equity Placement Agreement with L1 Capital

June 9, 2022

Strategic manufacturing partnership with WuXi ATU

April 12, 2022

Security Class Reinstatement to Quotation CHMO

March 27, 2022

CDH17 car t preclinical data featured in nature cancer

March 23, 2022

Completion of retail component of Entitlement Offer

March 22, 2022

Security Class Suspension from Quotation CHMO

March 20, 2022

Final Results in Phase 1 Trial of CORE NK Platform

March 6, 2022

Chimeric partners with be the match biotherapies

March 4, 2022

Successful completion of Institutional Entitlement Offer

February 22, 2022

Entitlement Offer to raise approximately $18.1 million

February 21, 2022

Encouraging data from 2nd dose cohort in CLTX CAR T trial

February 7, 2022

Sponsored Research Agreement with University of Pennsylvania

January 31, 2022

Chimeric receives US patent covering CLTX CAR technology

January 26, 2022

Transformative Portfolio Expansion Presentation

November 30, 2021

CLTX CAR T data shows regional control of tumour recurrence

November 21, 2021

Cltx car t presents positive initial phase 1 clinical data

November 14, 2021

First milestone on path to CDH17 car t clinical trial

October 21, 2021

European patent granted for CLTX technology used in CHM 1101

September 23, 2021

Partnership with OncoBay Clinical to advance CHM 1101

September 2, 2021

Preliminary Final Report

August 31, 2021

Chimeric Appoints Jennifer Chow as CEO & MD

August 30, 2021

IND clearance received from US FDA for CHM 1101

August 19, 2021

Chimeric licenses novel solid tumor CAR T therapy from Penn

July 27, 2021

Second Dose Cohort Initiated in CLTX CAR T Phase 1 Trial

May 23, 2021

Appendix 4C - quarterly

April 23, 2021

Successful Completion of First Patient Cohort Phase 1 Trial

April 21, 2021

Successful Completion of Dosing in First Patient Cohort

March 17, 2021

← Newer news releases

Decks

The 5 newest of 23 decks. Every deck is listed under its year.